reason report
prevent migrain readout top investor question
bottom line follow-up note preview note
month ago focus rimegep phase migrain
prevent studi report soon
mani discuss investor regard event
summar top five debat convers
addit refresh upside/downsid viewpoint
reiter outperform pt continu believ
like outcom posit trial efficaci data slightli
rang inject cgrp close monthli
highlight five key investor debat pg prevent
data releas delay compani chang studi
protocol expect around bar efficaci high
closer placebo-adjust mmd improv
size migrain market opportun given first two year
sale inject cgrp investor expect
stock risk/reward good given expect alreadi
high success trial rimegep label broad
inclus criteria prevent studi skew episod
chronic patient also cgrp data recap pg
believ investor focu prevent readout heighten
follow recent gener anxieti disord gad trial failur
troriluzol revis upside/downsid view
event remind pt attribut sotp valuat
rimegep prevent po hear
investor good news studi hit primari endpoint
meet mmd bar efficaci would bring stock current
level rang fail studi would lower
stock rang view upsid make sens
posit studi would move po would add
pt howev think downsid rang discuss seem
harsh vs valuat model would reflect stock
high rang even without prevent indic
also acknowledg investor disappoint usual drive
stock lower neg sentiment
short term addit hear investor happi
time recent capit rais remain concern
biohaven need rais addit fund compet allergan
mp neg tone around stock gener
investor howev stock dip low bad
news think would find support stock quickli rebound
least back mid continu insid
compani inform svb leerink llc research
revenu million non-gaap ep basic
pleas refer page import disclosur price chart analyst certif
rx trend deriv iqvia inc
sotp cash flow
net debt total capit
year price history/av daili volume mil
concern prevent data releas delay compani chang
true manag indic us chang plan chang
prevent studi protocol rather unblind data manag indic simpli
wait confirm fda statist analysi plan sap biohaven
one studi manag want sure fda suggest chang
unblind said manag note still doesnt expect issu fda
regard sap expect hear back fda soon alreadi close
day sinc file accept
concern expect around bar efficaci high closer
base convers investor tri push thesi
major investor understand allergan atogep phase data show
placebo-adjust reduct mean mmd achiev rang differ
dose regimen highest dose abl achiev wherea lower
dose closer mmd importantli phase result high dose regimen
also notabl show higher side effect could limit regimen use practic
concern size migrain market opportun given first two year
inject calcitonin gene-rel peptid cgrp sale investor expect
growth inject cgrp market slow steadi continu add
new patient per week market dont view number patient real issu
instead think issu price payer success play
three compani payer dont see meaning differenti among
three product addit allergan oral ubrelvy/ubrogep solid launch far iqvia
captur rx week rx week rx week thu demonstr
zero-sum game inject cgrp unlik inject expect oral
therapi eventu driven primari care market
concern risk/reward stock good given expect alreadi high
believ probabl true investor sentiment perspect convers
think invest commun expect posit studi prevent henc may
downsid upsid indic think upside/downsid rang
good news stock goe bad news stock goe
rang howev seen fail cgrp studi believ probabl success
good
concern rimegep label broad inclus criteria
prevent studi skew episod vs chronic patient
sure import actual label regard issu real practic
think biohaven care includ episod chronic migrain patient
manag indic studi popul patient averag prevent
trial popul mmd baselin gener manag believ
expect across episod chronic patient popul real world hile dual episod
chronic migrain patient enrol singl trial differ inject cgrp
approv manag sound confid one studi includ type patient
good enough broad label
summari phase data market inject cgrp aimovig
emgal ajovi upcom iv cgrp eptinezumab
monthli
migrain day placebo-
monthli
migrain day placebo-
regard primari endpoint episod migrain iv/inject cgrp pbo-adjust reduct
mmd chronic migrain pbo-adjust reduct mmd
episod migrain patient baselin mean migrain day per month
chronic migrain patient baselin bit vari mean migrain day per month
endpoint mean chang bl monthli migrain bl monthli acut migraine-specif medic bl mean migrain primari cm primari endpoint chang bl monthli migrain day least moder sever easi comparison includ chang bl monthli migrain day sever associ bl chronic migrain phase dataiv cgrpalder ph promis ph ph regainteva ph cm inject endpoint mean chang bl monthli migrain bl monthli acut migraine-specif medic bl mean migrain primari ph striveteva phase emweek cgrplilli ph phase ph ariseepisod migrain phase dataiv cgrpalder phase promis biohaven hold compani ltd
summari phase efficaci data agn atogep oral
cgrp seek indic migrain prevent
comparison episod
migrain iv/inject
cgrp reduct
mmd see prior
page data
lack stat-sig
atogep dose may
due high placebo respons
qd daili
exploratori analysi
primari endpoint episod migrain atogep achiev day pbo-adjust reduct
mmd realm achiev injectable/iv cgrp
atogep arm separ pbo respond analysi may due placebo effect
publish data avail atogep chronic migrain studi still recruit per clinicaltri gov
endpoint mean chang bl monthli migrain bl mean migrain primari cgrpallergan phase migrain phase data biohaven hold compani ltd
summari phase safeti data agn atogep oral
cgrp seek indic migrain prevent
treatment-emerg advers event atogep safeti popul
twice rate
teae vs pbo
teae report patient atogep treatment group patient placebo group
common teae atogep group nausea upper respiratori tract infect nasopharyng constip
total patient atogep placebo report seriou none consid treatment-rel
seriou treatment-rel advers event observ across atogep dose
constip rate interest light anecdot physician comment see higher constip amgen
aimovig post-launch recent aimovig label chang includ new constip warn
constip atogep qd bid dose respect
aimovig constip dose constip dose clinic trial
data support conserv view atogep long-term chronic use daili twice daili possibl
patient might develop safeti signal acut migrain treatment
summari long-term open-label safeti data suggest rimegep
potenti effect migrain prevent
design long-term safeti studi
fixed-dos cohort reduct migrain day
mean reduct
migrain days/month
month subject
reduct migrain day subject
migrain days/month
as-need prn patient moderate-to-sever
migrain attack per month take rimegep mg prn
fixed-dos qod prn cohort moderate-to-sever
migrain attack per month take rimegep mg qod
week supplement prn dose non-schedul dose day
prior treatment observ period
migrain day year
sever patient
exploratori analysi suggest intermitt dose rimegep qod prn may reduc overal number
headach day per month could point possibl effect migrain prevent
two key caveat data studi open label fix dose cohort
smaller figur on-going phase prevent trial per clinicaltri gov
know rimegep phase prevent trial design
enrol criteria possibl efficaci analys
design phase rimegep migrain prevent studi
migrain day
migrain day
year histori migrain with/without aura age onset migrain prior year old
migrain attack averag last hour untreat
migrain attack moderate-to-sever intens per month within last month prior
qod everi day
migrain day observ period
headach day observ period
subject prophylact migrain medic allow remain prophylact agent dose
stabl least month prior screen visit dose stabl studi
chang baselin mean
number migrain day per
month measur
double-blind phase
studi
assess week
mean number rescu
hepatic-rel treatment
mean chang baselin
mean chang baselin
disclos clinicaltri gov assum day rimegep long-term safeti studi observ period
think like analysi primari endpoint full popul mmd
probabl includ episod chronic migrain patient
henc could difficult compar rimegep result inject cgrp separ
episod chronic migrain pivot trial blend two group
think migrain space signific market brand acut segment under-appreci
biohaven monet strong rimegep clinic profil potenti go alon strategi like
glutam platform/pipelin get minim attent signific focu calcitonin gene-rel peptid
cgrp platform compani multipl shot goal area could sourc upsid surpris
recent in-licens product multipl system atrophi amyotroph later sclerosi al
offer addit opportun product even convers yet
manag strong scientif background neurosci expect continu use busi develop
continu build pipelin
pt base sotp analysi forecast cash flow discount rate
rimegep may get approv may get black box warn liver toxic signal emerg clinic trial
rimegep label may still get black box warn liver toxic due fda appli full cgrp class even
issu doesnt emerg clinic trial
acut market smaller forecast due lack differenti gener triptan and/or payer restrict
higher expect
biohaven struggl compet larger competitor allergan lilli choos go alon
investor skeptic glutam pipelin sinc phase trial failur spinocerebellar ataxia sca
marc goodman certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori ltd
creat bluematrix
pt base sotp analysi forecast cash flow discount rate
risk valuat
rimegep may get approv may get black box warn liver toxic signal emerg clinic trial
rimegep label may still get black box warn liver toxic due fda appli full cgrp class
even issu doesnt emerg clinic trial
acut market smaller forecast due lack differenti gener triptan and/or payer
restrict higher expect
biohaven struggl compet larger competitor allergan lilli choos go alon
investor skeptic glutam pipelin sinc phase trial failur spinocerebellar ataxia
rate price target histori compani
leerink place outperform rate octob
creat bluematrix
sinc suspend coverag share longer put forth valuat
risk valuat
sinc suspend coverag longer put forth risk valuat
rate price target histori allergan plc
leerink place outperform rate juli
creat bluematrix
pt base deal dynam
risk valuat
unlik instanc deal fail close current unforeseen reason
rate price target histori amgen inc
leerink place market perform rate februari
creat bluematrix
price target inc base averag three approach believ
reason basi valu stock today approach simpl price earn multipl larg cap us
eu larg cap biopharma stock celg sni rhhbi gsk nv
price sale multipl larg cap biotechnolog pharma compani novo nv
discount cash flow dcf use rel multipl larg cap biopharma compani
ep appli ep estim give one year futur valu use
establish larg cap futur revenu multipl sale appli revenu forecast
give futur valu final dcf valuat base current outlook compani exist
product probability-weight revenu contribut late-stag pipelin program discount
compani wacc give fair valu today averag three approach give
price target
risk valuat
risk view outlook valuat includ major chang label price
reimburs coverag compani legaci product failur compani growth portfolio achiev
futur sale forecast risk includ develop delay disappoint earlier stage pipelin asset
earlier signific eros compani legaci product biosimilar innov competit
shortfal compani effort improv oper margin would also materi affect outlook valuat
would larg dilut acquisit therapeut area platform
rate price target histori teva pharmaceut ltd teva
leerink place outperform rate teva march
creat bluematrix
price target base ebitda ev/ebitda multipl valuat includ
cash outflow base estim pv potenti damag relat on-going opioid
risk valuat
continu delay new gener opportun slower-than-anticip ramp ajovi headlin risk
gener price fix opioid lawsuit could result teva trade lower price target addit delay
gener competit copaxon proair along faster growth austedo could result teva trade
price target
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
